Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2011

01.08.2011 | Epidemiology

Improved web-based calculators for predicting breast carcinoma outcomes

verfasst von: James S. Michaelson, L. Leon Chen, Devon Bush, Allan Fong, Barbara Smith, Jerry Younger

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

We describe a set of web-based calculators, available at http://​www.​CancerMath.​net, which estimate the risk of breast carcinoma death, the reduction in life expectancy, and the impact of various adjuvant treatment choices. The published SNAP method of the binary biological model of cancer metastasis uses information on tumor size, nodal status, and other prognostic factors to accurately estimate of breast cancer lethality at 15 years after diagnosis. By combining these 15-year lethality estimates with data on the breast cancer hazard function, breast cancer lethality can be estimated at each of the 15 years after diagnosis. A web-based calculator was then created to visualize the estimated lethality with and without a range of adjuvant therapy options at any of the 15 years after diagnosis, and enable conditional survival calculations. NIH population data was used to estimate non-breast-cancer chance of death. The accuracy of the calculators was tested against two large breast carcinoma datasets: 7,907 patients seen at two academic hospitals and 362,491 patients from the SEER national dataset. The calculators were found to be highly accurate and specific, as seen by their capacity for stratifying patients into groups differing by as little as a 2% risk of death, and accurately accounting for nodal status, histology, grade, age, and hormone receptor status. Our breast carcinoma calculators provide accurate and useful estimates of the risk of death, which can aid in analysis of the various adjuvant therapy options available to each patient.
Literatur
1.
Zurück zum Zitat Lundin J, Lundin M, Isola J et al (2003) A web-based system for individualised survival estimation in breast cancer. BMJ 326:29PubMedCrossRef Lundin J, Lundin M, Isola J et al (2003) A web-based system for individualised survival estimation in breast cancer. BMJ 326:29PubMedCrossRef
2.
Zurück zum Zitat Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991PubMed Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991PubMed
3.
Zurück zum Zitat Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23(12):2716–2725PubMedCrossRef Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23(12):2716–2725PubMedCrossRef
4.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet 365(9472):1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet 365(9472):1687–1717CrossRef
5.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371:29–40CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371:29–40CrossRef
7.
Zurück zum Zitat Michaelson JS et al (2009) How cancer at the primary site and in the nodes contributes to lethality. Cancer 115(21):5095–5107PubMedCrossRef Michaelson JS et al (2009) How cancer at the primary site and in the nodes contributes to lethality. Cancer 115(21):5095–5107PubMedCrossRef
8.
Zurück zum Zitat Michaelson JS et al (2009) Why cancer at the primary site and in the nodes contributes to lethality. Cancer 115(21):5084–5094PubMedCrossRef Michaelson JS et al (2009) Why cancer at the primary site and in the nodes contributes to lethality. Cancer 115(21):5084–5094PubMedCrossRef
9.
Zurück zum Zitat Michaelson JS et al (2009) The impact of primary tumor size, nodal status, and other prognostic factors on the risk of cancer death. CANCER 115(21):5071–5083PubMedCrossRef Michaelson JS et al (2009) The impact of primary tumor size, nodal status, and other prognostic factors on the risk of cancer death. CANCER 115(21):5071–5083PubMedCrossRef
11.
Zurück zum Zitat Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J (2002) Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst 94(21):1626–1634PubMedCrossRef Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J (2002) Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst 94(21):1626–1634PubMedCrossRef
13.
Zurück zum Zitat Karrison TG, Ferguson DJ, Meier P (1991) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91:80–85CrossRef Karrison TG, Ferguson DJ, Meier P (1991) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91:80–85CrossRef
14.
Zurück zum Zitat Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 295(14):1658–1667PubMedCrossRef Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 295(14):1658–1667PubMedCrossRef
15.
Zurück zum Zitat Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J (2009) Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 27(2):214–219PubMedCrossRef Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J (2009) Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 27(2):214–219PubMedCrossRef
16.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer Staging Manual, 7th edn. Springer, Berlin Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer Staging Manual, 7th edn. Springer, Berlin
17.
Zurück zum Zitat Michaelson JS (2001) Using information on breast cancer growth, spread, and detectability to find the best ways to use screening to reduce breast cancer death. J Woman’s Imaging 3:54–57CrossRef Michaelson JS (2001) Using information on breast cancer growth, spread, and detectability to find the best ways to use screening to reduce breast cancer death. J Woman’s Imaging 3:54–57CrossRef
18.
Zurück zum Zitat Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L, Cancer Leukemia, Group B, Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351(10):971–977PubMedCrossRef Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L, Cancer Leukemia, Group B, Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351(10):971–977PubMedCrossRef
19.
Zurück zum Zitat Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM, Olivotto IA (2004) Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. Engl J Med 351(10):963–970CrossRef Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM, Olivotto IA (2004) Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. Engl J Med 351(10):963–970CrossRef
20.
Zurück zum Zitat Michaelson J, Halpern E, Kopans D (1999) A computer simulation method for estimating the optimal intervals for breast cancer screening. Radiology 212:551–560PubMed Michaelson J, Halpern E, Kopans D (1999) A computer simulation method for estimating the optimal intervals for breast cancer screening. Radiology 212:551–560PubMed
21.
Zurück zum Zitat Michaelson JS, Silverstein M, Wyatt J, Weber G, Moore R, Kopans DB, Hughes K (2002) Predicting the survival of patients with breast carcinoma using tumor size. CANCER 95:713–723PubMedCrossRef Michaelson JS, Silverstein M, Wyatt J, Weber G, Moore R, Kopans DB, Hughes K (2002) Predicting the survival of patients with breast carcinoma using tumor size. CANCER 95:713–723PubMedCrossRef
22.
Zurück zum Zitat Hughes K, Tanabe K, Smith B, Michaelson J (2004) Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer 101:495–507PubMedCrossRef Hughes K, Tanabe K, Smith B, Michaelson J (2004) Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer 101:495–507PubMedCrossRef
23.
Zurück zum Zitat Michaelson J (2007) Mammographic screening: impact on survival. In: Hayat MA (ed) Cancer imaging. Elsevier, Amsterdam Michaelson J (2007) Mammographic screening: impact on survival. In: Hayat MA (ed) Cancer imaging. Elsevier, Amsterdam
24.
Zurück zum Zitat National Vital Statistics Reports Vol. 54 No. 14, April 19, 2006, United States Life Tables (2003) National Vital Statistics Reports Vol. 54 No. 14, April 19, 2006, United States Life Tables (2003)
25.
Zurück zum Zitat Mook S, Schmidt M, Rutgers EJ et al (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 10:1070–1076PubMedCrossRef Mook S, Schmidt M, Rutgers EJ et al (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 10:1070–1076PubMedCrossRef
Metadaten
Titel
Improved web-based calculators for predicting breast carcinoma outcomes
verfasst von
James S. Michaelson
L. Leon Chen
Devon Bush
Allan Fong
Barbara Smith
Jerry Younger
Publikationsdatum
01.08.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1366-9

Weitere Artikel der Ausgabe 3/2011

Breast Cancer Research and Treatment 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.